Improvements throughout the pipeline bring greater biologic yields, as well as higher quality. by Raymond E Peck, CEO of VxP Biologics Improvements throughout the pipeline bring greater biologic yields, as well as lower costs. Bioprocessing is the production of natural or genetically manipulated cells (or other organic parts). In the field of biologic pharmaceuticals, bioprocessing [...]
The creation, production and storage of viral vectors all pose highly unusual challenges. by Susan Thompson, Technical Director at VxP Biologics Traditional viral vaccines use attenuated or inactivated forms of viruses to trigger and “train” the body’s immune responses. In recent years, however, pharmaceutical developers have also begun to use viruses as vectors to deliver [...]
Advances in Biological Safety Level 3 technology offer advantages for agile biologic developers. by Raymond E Peck, CEO of VxP Biologics Many types of biologics include live populations of organisms, some of which may be highly infectious in active form. Vaccines, in particular, often contain deadly bacteria and viruses in live but attenuated forms. The [...]
Emerging technologies offer exciting opportunities for the development of novel therapies. by Susan Thompson, Technical Director at VxP Biologics Although commercial sales are certainly a desirable target for pharmaceutical development, they’re far from the only reason to invest in new products. In a number of fields, pharma developers are partnering with contract manufacturing organizations (CMOs) [...]
